Protection against mucosally transmitted infections probably requires immunity at the site of pathogen entry 1 , yet there are no mucosal adjuvant formulations licensed for human use. Polyethyleneimine (PEI) represents a family of organic polycations used as nucleic acid transfection reagents in vitro and DNA vaccine delivery vehicles in vivo 2,3 . Here we show that diverse PEI forms have potent mucosal adjuvant activity for viral subunit glycoprotein antigens. A single intranasal administration of influenza hemagglutinin or herpes simplex virus type-2 (HSV-2) glycoprotein D with PEI elicited robust antibody-mediated protection from an otherwise lethal infection, and was superior to existing experimental mucosal adjuvants. PEI formed nanoscale complexes with antigen, which were taken up by antigen-presenting cells in vitro and in vivo, promoted dendritic cell trafficking to draining lymph nodes and induced non-proinflammatory cytokine responses. PEI adjuvanticity required release of host double-stranded DNA that triggered Irf3-dependent signaling. PEI therefore merits further investigation as a mucosal adjuvant for human use.
Although immune responses can be elicited at mucosal surfaces by systemic immunization, the compartmentalization of the immune system means that this may be suboptimal for protection from mucosal pathogens 1 . Despite extensive efforts, no adjuvanted mucosal vaccine targeting major mucosally transmitted infectious diseases, such as influenza A, HSV-2 or HIV-1, has been licensed for use in humans 4 . Currently available experimental mucosal adjuvants include cholera holotoxin, the cholera toxin B subunit (CTB), the Escherichia coli-derived heat-labile enterotoxin, α-galactosylceramide (αGalCer, a CD1 ligand), CpG-containing oligodeoxynucleotides (CpG) and the double-stranded RNA analog polyinosinic-polycytidylic acid (poly(I:C)). Despite showing promise in terms of immune-stimulating activity, these adjuvants have yet to be licensed for human use, in large part because of safety concerns linked to local or systemic toxicity and reactogenicity [5] [6] [7] [8] . Receptor agonist-based adjuvants, such as CpG (a toll-like receptor (TLR) 9 ligand) and poly(I:C) (a TLR3 ligand), have well-defined mechanisms of action 9 . Other adjuvants, however, including aluminum salts, do not require TLR signaling for immune activation, implying the existence of distinct adjuvantelicited immune activation pathways [10] [11] [12] .
PEI is a cationic polymer, synthesized in various forms including linear or branched and high or low molecular weight species, that is widely used as a gene transduction agent. PEI forms complexes with nucleic acids through electrostatic interactions forming nanoscale 'polyplexes' . These polyplexes bind cell surface heparan sulfate proteoglycans and enter cells through endocytosis 3 . During endosomal acidification, buffering by PEI results in osmotic rupture of the endosome, allowing entry of the polyplexes directly into the cytoplasm 3 . In addition to their use as gene transduction agents, PEI has been used to increase the immunogenicity of DNA vaccines 13, 14 . However, it is unclear from these studies whether PEI acts solely by protecting DNA and enhancing its cellular targeting and uptake, or whether PEI has intrinsic immune-activating properties in vivo.
As PEI can efficiently deliver cargo into cells that express heparan sulfate proteoglycans, such as antigen-presenting cells (APC) 15, 16 we hypothesized that it might also function as a mucosal adjuvant for glycoprotein antigens. To address this, we immunized mice twice intranasally with a weakly immunogenic, endotoxin-free, experimental viral vaccine antigen-recombinant envelope glycoprotein gp140 derived from the HIV-1 CN54 isolate-alone, with the known mucosal adjuvant CTB, or complexed with various PEI forms. We found that antigen-specific IgG titers in the serum were ~100-fold higher when gp140 was administered with PEI than alone and up to six-fold higher than those elicited by CTB (Fig. 1a) . As HIV-1 is transmitted predominantly through the genital mucosae, we analyzed IgA levels in vaginal lavages. In these experiments, linear PEI forms were not more potent than CTB, whereas branched PEI forms of 750 kD (B750) and 25 kD (B25) gave titers of antigen-specific mucosal 8 8 4 VOLUME 30 NUMBER 9 SEPTEMBER 2012 nature biotechnology l e t t e r s IgA more than tenfold higher than those elicited by CTB (P < 0.05, ANOVA with Bonferroni correction, Fig. 1b) . As PEI-B750 and PEI-B25 had similar levels of adjuvant activity and PEI-B25 is the beststudied form in terms of gene delivery 17 , we further characterized the safety and adjuvanticity of PEI-B25.
When PEI is used as a DNA transfection reagent, high levels are known to be cytotoxic in vitro, but little is known about the toxicity of PEI in vivo 18 . We found that a single intranasal dose of gp140 with either 10 or 20 µg PEI-B25 was safe and equivalently immunogenic ( Supplementary Fig. 1a-c) . Similarly safe were cholera holotoxin, CTB and poly(lactic-co-glycolic acid) nanoparticles (PLGA, Supplementary Fig. 1d,e) used at, or above, standard doses (Supplementary Table 1) . By contrast, 20 µg CpG promoted significant (P < 0.05, ANOVA followed by Dunnett's test) weight loss. Despite this, neither PEI nor CpG obviously modified the nasal epithelium when compared with PBS alone (Supplementary Fig. 1f) , although further investigation is required to rule out any localized neurological effects 19 .
We compared the adjuvanticity of PEI with other prominent experimental mucosal adjuvants. Twenty-one days after a single intranasal gp140 administration, we observed serum antigenspecific IgG endpoint titers of ~10 3 for PEI, CTB and CpG, which were substantially greater than the titers induced by gp140 alone or when formulated with PGLA (Fig. 1c) . After a booster immunization, we observed a similar pattern of responses with higher endpoint serum IgG titers (Supplementary Fig. 2a) . Notably, 2 weeks after the booster PEI induced significantly (P < 0.05, ANOVA followed by Dunnett's test) higher avidity antigen-specific IgG than cholera holotoxin, CTB or CpG (Fig. 1d) , implying enhanced affinity maturation by PEI. Moreover, gp140-specific antibodies induced by PEI preferentially recognized gp140 in its native conformation (Fig. 1e) , suggesting that PEI may protect the immunizing antigen from denaturation and degradation in vivo, possibly by a mechanism analogous to the compaction and chaperoning of DNA. By contrast with CpG, which elicited an IgG2a-biased response, PEI, cholera holotoxin and CTB elicited a dominant IgG1 isotype (Fig. 1f) consistent with the bias toward T helper type 2 (T H 2) immunity previously reported for CTB 20 .
To further investigate a role for PEI in T H 2-type immune biasing, we used antigen to in vitro restimulate lymphocytes derived from spleen or nasal epithelium-draining cervical lymph node (CLN). Proliferation of splenocytes and CLN cells from mice that received antigen-PEI or antigen-CTB was significantly increased (P < 0.01 and P < 0.001, respectively; ANOVA followed by Dunnett's test) compared to antigen alone (Supplementary Fig. 2b ), demonstrating that adjuvanted intranasal immunization induced both local and systemic T-cell activation. However, the ratio of CLN cells to splenocyte proliferation was significantly (P < 0.01, two-tailed t-test) greater in PEI-immunized mice than in CTB-immunized mice, suggesting that PEI acts more locally than CTB (Fig. 1g) . Splenocyte and CLN cell cytokine release profiles confirmed a T H 2 bias. CTB and PEI induced similar levels of interleukin (IL)-4, IL-5 and IL-13, but PEI induced lower levels of the pro-inflammatory cytokines IL-17, IFN-γ and TNF-α ( Supplementary  Fig. 2c,d ). As previously reported 21 , CTB induced high levels of the pro-inflammatory cytokine IL-17. Comparison of ratios of IL-17/IL-4, IL-17/IL-2 and IL-2/IL-4 revealed that PEI induced significantly (P < 0.01, Kruskal-Wallis followed by Dunn's test) lower IL-17 than CTB both in spleen and local lymph nodes (Supplementary Fig. 2e-j) . (j,k) Disease score (j) and Kaplan-Meier survival plots (k) for immunized mice after highly pathogenic vaginal HSV-2 challenge. C57Bl/6 mice, n = 7. All data are presented as mean of replicates from individual experiments ± s.e.m.; n.s., not significant (P > 0.05); *, P < 0.05; **, P < 0.01; ***, P < 0.001. CT, cholera holotoxin; CTB, cholera toxin B subunit; HA, hemagglutinin; gD, glycoprotein D.
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We analyzed species-related PEI activity in rabbits immunized intranasally with HIV-1 gp140 alone or with equivalent doses of PEI or CTB. PEI increased antigen-specific serum IgG responses by 16-fold more than a safe dose of CTB, which gave titers statistically indistinguishable from gp140 alone (Supplementary Fig. 3a) . Vaginal IgG titers were lower than serum titers but confirmed the trend with three-fold greater responses in the PEI group compared to CTB, whereas vaginal antigen-specific IgA was not detected (Supplementary Fig. 3b) .
We next sought to determine the efficacy of PEI as an adjuvant in a model of respiratory infectious disease. After priming with purified influenza A/PR8 hemagglutinin alone, formulated in PEI or in other mucosal adjuvants at standard doses (Supplementary Table 1 ), we challenged mice intranasally with a pathogenic dose of influenza A/PR8. Mice that received no antigen, antigen alone or antigen in αGalCer had severe (15-25%) weight loss, whereas mice that received antigen in CTB only exhibited moderate (~10%) weight loss (Fig. 1h) . Notably, mice immunized with antigen in PEI were completely protected from weight loss, showing significantly (P < 0.05, Kruskal-Wallis followed by Dunn's test) enhanced protection compared to CTB or αGalCer ( Supplementary Fig. 4a ), mirrored by complete protection from an otherwise lethal influenza A/PR8 challenge (Fig. 1i) . Of note, PEI-elicited hemagglutininspecifc IgG showed an enhanced ratio of native to denatured antigen binding compared to other groups ( Supplementary Fig. 4b ), suggesting that PEI-induced antibodies would preferentially bind native viral hemagglutinin. Similar titers of antigen-specific serum IgG1, IgG2a and IgA were elicited by all adjuvants, and IgA titer correlated significantly (P < 0.05, Spearman-correlation of log-transformed titers) with reduced disease (Supplementary Fig. 4c,d) . Similarly, titers of antigen-specific IgA but not IgG in the bronchoalveolar lavage correlated with protection from disease ( Supplementary Fig. 4e-g ).
We also compared PEI and CTB in a more conventional format using prime and booster immunizations to increase adaptive immune responses. Again, PEI provided complete protection from disease, whereas CTB-treated mice showed a trend toward weight loss ( Supplementary Fig. 5a,b) . Antigen-specific IgG levels in the serum were significantly (P < 0.01, ANOVA followed by Dunnett's test) higher for PEI than for CTB after the prime but were equivalent after the booster (Supplementary Fig. 5c ). In this format, both serum IgG1 and IgA titers correlated with protection from disease ( Supplementary Fig. 5d,e) , and median antibody avidity was tenfold higher for PEI than CTB (Supplementary Fig. 5f ). We conclude from these experiments that the superior protection by PEI from influenzamediated disease is likely to reflect increased avidity and/or recognition of native antigen by antibodies elicited by this adjuvant.
To investigate whether intranasal administration of antigen in PEI induced protective responses at a distant mucosal surface, we adopted an established mouse model of mucosal immunization with recombinant HSV-2 glycoprotein D followed by vaginal challenge with an otherwise lethal dose of HSV-2 (ref. 22 ). Mice were primed and boosted twice intranasally with glycoprotein D alone, in cholera holotoxin, αGalCer or in PEI. We also challenged mice primed but not boosted with glycoprotein D alone or glycoprotein D in PEI. Mice receiving three immunizations of glycoprotein D in αGalCer, cholera holotoxin and PEI were completely protected from disease and terminal weight loss, whereas mock-immunized mice or those receiving glycoprotein D alone were not protected (Fig. 1j,k) . Notably, mice receiving a single dose of glycoprotein D in PEI were largely protected from disease and 80% protected from terminal weight loss, by contrast with glycoprotein D alone (Fig. 1j,k and P < 0.05, ANOVA with Bonferroni correction, Supplementary  Fig. 6a ). Before challenge, antigen-specific serum IgG titers were significantly (P < 0.001, ANOVA with Bonferroni correction) greater in mice receiving adjuvanted glycoprotein D compared to mice receiving glycoprotein D alone (Supplementary Fig. 6b ). Antigenspecific vaginal IgA was undetectable.
The robust adaptive immunity induced by PEI suggested antigen targeting to APC either directly, or indirectly by targeting to mucosal epithelial cells followed by cell death and APC uptake, or both. As polycationic PEI forms complexes with polyanionic nucleic acids promoting cellular uptake, we hypothesized that the same might hold for glycoprotein antigens with a net negative surface charge, such as gp140 (ref. 23) . To investigate this, we performed surface plasmon resonance binding assays. Soluble gp140 interacted with immobilized PEI weakly but with a relatively slow off-rate, whereas immobilized gp140 interacted strongly with soluble PEI with fast on-rates and slow off-rates (Fig. 2a) . Use of PEI as an adjuvant will better mimic the first condition in which antigen binds polymeric PEI in solution. To further explore PEI-gp140 interactions, we carried out scanning electron microscopic analysis of PEI and gp140 alone, combined, or PEI complexed with DNA. We confirmed previous studies demonstrating that PEI alone appears as an amorphous matrix whereas PEI and DNA form globular polyplexes of 100-200 nm 24 (Fig. 2b) . By contrast, gp140 and PEI formed a distinct species of particle with an average diameter of 750 nm (Fig. 2b,c) , approximately two-to tenfold larger than particles formed between ovalbumin (OVA) and PEI 25 .
To test whether gp140-PEI particles were targeted for APC uptake in vitro, we treated bone marrow-derived dendritic cells (BMDCs) or an epithelial cell line with fluorochrome-labeled gp140 (gp140 647 ) or gp140 647 -PEI, and analyzed the cells by confocal microscopy and flow cytometry. Addition of gp140 647 alone gave diffuse low-level BMDC uptake, whereas gp140 647 with PEI yielded robust intracellular uptake of particulate complexes (Fig. 2d-f) . Epithelial cells were also efficiently targeted by gp140 647 -PEI (Fig. 2g) . To investigate PEI-antigen uptake and cellular recruitment in vivo, we inoculated mice intranasally with PEI-gp140 647 and evaluated antigen uptake of disaggregated nasal-associated lymphoid tissue (NALT) and draining CLN by flow cytometry. At 4 h after intranasal administration, PEI significantly enhanced gp140 647 uptake by epithelial cells (P < 0.001) and microfold cells (P < 0.01, two-tailed t-test) that express high levels of heparan sulfate proteoglycans targeted by PEI-DNA complexes 3 (Fig. 2h) . This PEI-mediated antigen targeting was accompanied by modest transient recruitment of neutrophils into the NALT and CLN (Fig. 2i and Supplementary Fig. 7c,d) , observed for many adjuvants and routes of immunization 11, 26 . At 24 h after administration, gp140 647 was primarily found associated with dendritic cells in draining CLN, and PEI mediated significant recruitment of dendritic cells and B cells (P < 0.001 and P < 0.01, respectively, two-tailed t-test) to CLN (Fig. 2j,k and Supplementary Fig. 7a,b) .
As PEI targets cargo to the cytoplasm 3 , we investigated its ability to enhance antigen cross-presentation in vitro and in vivo using an OVA model system. PEI-OVA-exposed BMDC significantly (P < 0.05, ANOVA followed by Dunnett's test) enhanced the response of B3Z T cells, a T-cell hybridoma activated by recognition of H-2K b in association with OVA (257-264) peptide ( Supplementary  Fig. 8a) , consistent with increased cross-priming in the presence of PEI in vitro observed previously 25 . However, there was no increase in the frequency of CLN gp140-specific CTLs induced in vivo by PEI after intranasal immunization ( Supplementary  Fig. 8b ). This finding is consistent with the lack of IFNγ secretion detected in gp140-restimulated lymphocytes from immunized npg l e t t e r s mice (Supplementary Fig. 2c,d ) and probably reflects insufficient PEI-induced T helper type 1 (T H 1)-biased help.
A major function of adjuvants is activation of innate immune responses that trigger adaptive immunity. We therefore studied a well-established mode of adjuvant mechanism, direct activation of APCs resulting in increased expression of costimulatory molecules and cytokine secretion 27 , by comparing immature BMDCs incubated in vitro with PEI to those activated by the TLR4-ligand lipopolysaccharide (LPS). LPS induced predicted upregulation of maturation markers CD40, CD86 and major histocompatibility (MHC) class-II, whereas PEI did not increase expression of these markers above control values, indicating the absence of direct maturation signals (Supplementary Fig. 9a,b) . Consistent with this result, PEI failed to activate two TLR reporter cell lines (Supplementary Fig. 9c,d ) and other reporter lines specific for individual TLRs (data not shown).
It was recently demonstrated that the aluminum-based adjuvant, alum, triggers the release of double-stranded (dsDNA) from dying cells, resulting in activation of other cells in an Irf3-dependent pathway 28 . As PEI exhibits varying degrees of cellular toxicity in vitro 18 , we hypothesized that this might liberate cellular dsDNA leading to activation of intracellular dsDNA sensors. Indeed, PEI induced apoptosis and cell death in the lung epithelial cell line LA-4 ( Supplementary  Fig. 10a,b) . Although alum-released dsDNA triggers cytoplasmic DNA sensors 28 , it is not clear how released host dsDNA crosses the plasma membrane to engage these sensors. We tested the targeting by alum and PEI of synthetic dsDNA (poly(dA:dT)) to the cytoplasm of B16-blue type-I interferon reporter cells. Poly(dA:dT) combined with alum or PEI induced significant (P < 0.001, two-way ANOVA) activation of reporter cells, with PEI-induced activation about fourfold higher than that with alum (Fig. 3a,b) .
To investigate DNA release in vivo, we administered PEI or alum intraperitoneally and assayed peritoneal lavage for free dsDNA. Both PEI and alum mediated release of highly significant (P < 0.001, ANOVA followed by Dunnett's test) amounts of dsDNA into the lavage (Fig. 3c) . This prompted us to carry out intranasal immunization of npg l e t t e r s mice with PEI and gp140 followed by intranasal DNase-I treatment 28 to evaluate the effect of degrading released DNA on events triggering adaptive immunity. DNAse treatment significantly (P < 0.05, ANOVA with Bonferroni correction) reduced PEI-induced, but not αGalCer-or cholera holotoxin-induced, antigen-specific antibody responses, demonstrating that DNase activity has an adjuvant-specific downmodulating effect (Fig. 3d) . We examined the possible role of Irf3 in the DNA-mediated adjuvant effect of PEI by intranasal administration of PEI and gp140 to Irf3 −/− mice followed by assay of antigenspecific IgG1. Similar IgG1 responses to antigen alone were observed in both groups, indicating that Irf3 −/− mice were not generally less sensitive to intranasal immunization. By contrast, PEI activity was reduced by 41-fold (P < 0.01, ANOVA with Bonferroni correction) in the Irf3 −/− mice compared to wild-type controls, demonstrating strong dependence upon this pathway for PEI adjuvanticity (Fig. 3e,f) . We observed a non-significant (P > 0.05, ANOVA with Bonferroni correction) reduction (sevenfold) in IgG1 titer for cholera holotoxin, suggesting a weak or absent Irf3 requirement for this adjuvant. The reported lysosomal disruption by PEI implicit in its gene transduction activity 3 suggested that PEI might trigger the Nlrp3 inflammasome. Because the release of IL-1β is a hallmark of inflammasome activation that has been implicated in the adjuvant activity of alum 29 , we assayed IL-1β in lavage 4 h and 24 h after intraperitoneal PEI administration. At both time points, IL-1β levels were elevated (Supplementary Fig. 11a) . Treatment of bone marrow-derived macrophages (BMM) with LPS and alum as a positive control or LPS and PEI led to increased release of IL-1β and IL-18 ( Supplementary  Fig. 11b,c) . To confirm inflammasome assembly, we assayed caspase-1 activation 29, 30 in lysates of BMM that were unstimulated, PEI-treated, LPS-primed or LPS primed with PEI or ATP. Relative to untreated cells or cells treated with LPS alone, both PEI alone and PEI with LPS induced caspase-1 cleavage (Supplementary Fig. 11d) . We investigated inflammasome activation in the adjuvant activity of PEI by intranasally immunizing wild-type and Nlrp3 −/− mice with PEI and gp140. PEI with antigen induced higher antigen-specific total serum IgG titers compared with antigen alone that were equivalent in wild-type and Nlrp3 −/− mice (Supplementary Fig. 11e) . However, Nlrp3 −/− mice immunized with antigen and PEI showed a >20-fold increased level of specific IgG2c compared to wild type (P < 0.05, ANOVA with Bonferroni correction Supplementary  Fig. 11f,g ), whereas no significant isotype bias was observed with cholera holotoxin adjuvantation (Supplementary Fig. 11h-j) . These data show that Nlrp3 inflammasome function is not required for overall PEI adjuvant activity, but suggest that inflammasome activation biases adaptive immunity toward a T H 2 response.
This study describes both the innate and adaptive immuneactivating activities of PEI driving in vivo mucosal adjuvanticity. Innate immune pathways are activated by the release of intracellular dsDNA that acts as a damage-associated molecular pattern triggering the Irf3 interferon pathway through cytoplasmic DNA sensors. This mode of innate immune activation has recently been proposed for the TLR-independent adjuvant alum 28 . Another innate immune pathway activated by PEI is the inflammasome, potentially either through the lysosomal destabilizing activity of PEI 3 , or through release of other damage-associated molecular patterns, such as uric acid. We also show that PEI triggers an influx of APC to the site of immunization and associates with antigen to form nanoparticles that are efficiently taken up by APC. Thus, PEI acts at multiple levels to deliver adjuvant activity for glycoprotein antigens (Supplementary Fig. 12 ).
Several studies have demonstrated increased immunogenicity of vaccine DNA when formulated with PEI 14, 31 . However, the DNA delivery activity of PEI predicts neither that PEI will have intrinsic, innate immune-activating properties, nor that PEI will function as an adjuvant for non-DNA antigens. Although one recent study demonstrated NF-κB activation after in vitro treatment of BMDCs with PEI 14 , this does not imply adjuvant activity in vivo.
The minimal induction of proinflammatory cytokines and modest local infiltration of neutrophils by PEI suggests that this adjuvant is unlikely to elicit inflammation-induced tissue damage at sensitive mucosal surfaces and would be free of concerns relating to the consequences of high-level mucosal IL-17 induction, such as , not significant (P > 0.05); *, P < 0.05; **, P < 0.01; ***, P < 0.001.
npg l e t t e r s inflammation and autoimmunity 32 . The ability of PEI to induce protective immune responses to mucosal viral infection implies that the immune responses of neither the T H 1 nor the T H 17 subset of helper T cells are an absolute requirement. In line with a major role for antibodies as a dominant protective effector mechanism, we identified IgA and IgG as correlates of protection ( Supplementary Figs. 4 and 5) . The enhanced avidity and recognition of native antigen after PEI-adjuvantation are very encouraging, particularly for highly conformational antigens such as those tested here. Finally, the generalizable adjuvant activity of different PEIs suggests that potency and safety may be further optimized both for DNA and non-nucleic acid antigen delivery.
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Methods and any associated references are available in the online version of the paper.
and critically point-dried. After sputter coating with gold the samples were examined in a JOEL JSM 6390 scanning electron microscope.
In vitro antigen uptake assay. Fluorescently labeled gp140 647 antigen (2 µg/mL) was pre-incubated with PEI (0.1 µg/mL) or PBS for 3 h at 4 °C with shaking. Antigen, PEI or PEI-antigen polyplexes were then co-incubated with either BMDC or LA4 epithelial cells for 4 h at 37 °C in 24-well plates. Cells were then repeatedly washed in PBS and harvested by EDTA (5 mM) treatment. Antigen uptake was determined by flow cytometry in duplicate wells and data pooled from three independent experiments. In parallel assays, BMDCs were adhered to coverslips before 4 h incubation with either gp140 647 (2 µg/mL) or gp140 647 pre-incubated with PEI (0.1 µg/mL). Hoechst 34580 dye (2 µg/mL, Molecular Probes) and WGA 555 (wheat germ agglutinin, 5 µg/mL, Molecular Probes) staining was used in the final 10 min of incubation to label the nucleus and cell surface, respectively. Antigen or PEI-antigen uptake was then visualized by confocal microscopy via Olympus FV1000, IX81, 60× N/A (1.35) and FluoView software (Olympus).
In vitro apoptosis/cytotoxicity assay. The epithelial-derived cell line LA4 was co-incubated with increasing doses of PEI (0.01-10 µg/mL) for 18 h at 37 °C. Cells were then harvested by EDTA (5 mM) treatment followed by cell scraping and stained for viability using the LIVE/DEAD viability dye (Molecular Probes) followed by Annexin V staining (Molecular Probes) in appropriate buffers. Cell death/apoptosis was examined by flow cytometry via FACSCalibur (BD) and FlowJo software (Tree Star Inc).
In vivo recruitment and antigen uptake assay. Mice were immunized intranasally with PEI (20 µg/mL), gp140 647 (10 µg/mL) or PEI/gp140 647 polyplexes (2:1) and 4 or 24 h later NALT tissue and CLNs removed for analysis. Single-cell suspensions were prepared in PBS-EDTA (2 mM) by gentle teasing and then cells were passed through a sieve to remove aggregates. In vitro stimulation of BMDCs and BMMs. BMDCs were generated as described earlier 39 . For maturation, cells were incubated overnight with 1 µg/mL LPS (Sigma) or 10 µg/mL PEI (25 kDa, Sigma) and subsequently analyzed by flow cytometry using the following antibodies: MHC-II (2G9), CD16/CD32 (2.4G2), CD40 (3/23), CD80 (RM80), CD86 (GL1). BMMs were derived from bone marrow cells cultured for 7 d in R10 medium supplemented with 15% L-929 cell-conditioned medium. BMM were LPS-stimulated overnight or left unstimulated, followed by incubation with 15 µg/mL Alhydrogel (Alum), 20 µg/mL PEI or 4 h or 10 µg/mL ATP for 30 min. Secretion of IL-1β and IL-18 were measured by ELISA (R&D Systems and Bender Medsystems, respectively). Mature caspase-1 was detected in cell lysates separated by gel electrophoresis and subjected to western blot analysis using rabbit anti-caspase-1 (M-20, Santa Cruz Biotechnology) for visualization of Caspase-1 p10 (apparent MW 17 kDa as verified by blocking with M-20 peptide, data not shown).
In vitro cross-presentation assay. Splenic dendritic cells were isolated by digestion, density gradient centrifugation, followed by positive selection using αCD11c-microbeads (Miltenyi Biotec, Cologne, Germany) as per the manufacturer's instructions. Dendritic cell were pulsed with OVA (50 µg/mL) alone, OVA (50 µg/mL) pre-complexed with PEI (0.002-0.2 µg/mL), OVA (50 µg/mL) in the presence of CpG (1 µg/mL) or SIINFEKL peptide (20 µg/ mL) for 3 h at 37 °C. dendritic cell were washed and 5 × 10 4 cells co-incubated (1:1) with the lacZ-inducible SIINFEKL-specific CD8 + T-cell hybridoma B3Z, for 24 h at 37 °C. Hybridoma responses were assessed by intracellular β-galactosidase activity and read by spectrophotometer (OD 595nm/635nm).
In vivo CD8 + T-cell induction. C57Bl/6 mice were immunized four times intranasally with gp140 (10 µg) or gp140 + PEI (20 µg). Two weeks after the final booster, mice were euthanized and CLN removed and single-cell suspensions prepared. Lymphocytes were restimulated with medium, gp140 (50 µg/mL) or concanavalin A (1 µg/mL) at 37 °C for 4 h before Brefeldin A (10 µg/mL) added and cells incubated for a further 18 h. Cells were then washed and fixed in 4% paraformaldehyde before surface staining for CD8α (53-6.7), CD4 (GK1.5) and CD3ε (145-2C11). After further washing, cells were permeabilized in Perm/Wash buffer (BD) and stained for intracellular IFNγ (XMG1.2) and examined by CyAn ADP analysis (Beckman Coulter, USA) and FlowJo software (Tree Star Inc.). Absolute cell numbers were determined in parallel by flow cytometry using Liquid Counting Beads (BD).
